Study of matrix metalloproteinases and their tissue inhibitor in patients with ovarian tumors
https://doi.org/10.17650/1994-4098-2012-0-2-48-54
Abstract
We studied main matrix metalloproteinases (MMP) and their tissue inhibitors in tumors and blood serum of ovarian cancer, benign and borderline tumor patients. We revealed a coordinate increase of MMP-7 tumor expression and serum concentration in ovarian cancer that indicates it’s role as potential serological marker for ovarian cancer.
About the Authors
K. P. Lactionov
Federal State Budgetary Institution N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
N. V. Levkina
Federal State Budgetary Institution N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
D. N. Kushlinsky
Federal State Budgetary Institution N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. S. Hershtein
Federal State Budgetary Institution N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Статистика злокачественных новообразований в России и странах СНГ (состояние онкологической помощи, заболеваемость и смертность). Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ им. Н.Н. Блохина РАМН 2009;20 (3 Прил 1):52–122.
2. Жорданиа К.И. Злокачественные новообразования яичников. Энциклопедия клинической онкологии. М.: РОНЦ им. Н.Н. Блохина РАМН, 2004. С. 356–8.
3. Кадагидзе З.Г., Шелепова В.М. Роль опухолеассоциированных антигенов в диагностике онкогинекологических заболеваний. В кн.: Клиническая онко- гинекология. Руководство для врачей. Под ред. В.П. Козаченко. М.: Медицина, 2005. С. 49–61.
4. Visintin I., Feng Z., Longton G. et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14(4):1065–72.
5. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 2010;1803(1):103–20.
6. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161–74.
7. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92(8):827–39.
8. Sillanpaa S., Anttila M., Suhonen K. et
9. al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 2007;28(5):280–9.
10. Sillanpaa S., Anttila M., Voutilainen K. et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 2007;104(2):296–303.
11. Sillanpaa S., Anttila M., Voutilainen K. et al. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer 2006;119(8):1792–9.
12. Goldman S., Shalev E. MMPs and TIMPs in ovarian physiology and pathophysiology. Front Biosci 2004;9: 2474–83.
13. Huang L.W., Garrett A.P., Bell D.A. et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000;77(3):369–76.
14. Kenny H.A., Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009;8(5):683–8.
15. Sakata K., Shigemasa K., Nagai N., Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 2000;17(4):673–81.
Review
For citations:
Lactionov K.P., Levkina N.V., Kushlinsky D.N., Hershtein E.S. Study of matrix metalloproteinases and their tissue inhibitor in patients with ovarian tumors. Tumors of female reproductive system. 2012;(2):48-54. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-2-48-54
Views:
419
Email this article 